Search results
Showing 3316 to 3330 of 7691 results
This indicator has been withdrawn following discussions with the National Screening Committee.
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.
Technology appraisal submission templates and supporting documents
On this page, you'll find all the templates and supporting documents you need to make a technology appraisals submission. These templates have been...
NICE research projects and partners.
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
Should I stop my benzodiazepine or z-drug? Patient decision aid: summary Do not stop taking your benzodiazepine or z-drug suddenly What are...
This indicator covers the proportion of children and young people with diabetes who have had their glycated haemoglobin A1c (HbA1c) monitored in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG67
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Information, meeting dates and minutes of the medical technologies advisory committee
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged